As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely watched immunotherapy ivonescimab.

Pfizer’s stock climbed 2.4% in morning trading, while Merck shares gained 1.7%. As Cantor Fitzgerald analyst Carter Gould put it, Pfizer’s deal with 3SBio thrusts the company into the PD-1 ...

NEW YORK, May 20, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical ...